Eliezer Huberman, Ph.D.
Jingwu Zang, M.D., Ph.D.
Norman Barton, M.D., Ph.D.
Daniel R. Marshak, Ph.D.
Shelly Heimfeld, Ph.D.
Irun Cohen, M.D.
|
Advisors
|
|
Dr. Eliezer Huberman, Ph.D. – Chairman of the Scientific Advisory Board
Dr. Huberman served as Director of Biological & Biotechnological research at the Argonne National Laboratory from 1981 and as Professor of Microbiology, Molecular Genetics & Cell Biology, and Radiation & Cellular Oncology at the University of Chicago since 1982. Dr. Huberman received his Ph.D. in Genetics from the Weizmann Institute of Science in Israel in 1969. Dr. Huberman made pivotal contributions to cancer research, cellular differentiation and adult stem cells research. Dr. Huberman served on national and international committees including the National Academy of Sciences, National Cancer Institute, EPA and MIT, and as an Associate Editor of prominent scientific journals. Dr. Huberman has to his record more than 200 scientific papers, 6 patents and various awards including an Honorary Doctorate from the prestigious Engelhardt Institute of the Russian Academy of Sciences. Dr. Huberman leads an active research team at the Argonne Laboratory. Top Jingwu Zang, M.D., Ph.D. Dr. Zang has served as Professor of Neurology and Immunology at Baylor College of Medicine and Scientific Director of the Baylor-Methodist Multiple Sclerosis Center in Houston since 1996. Dr. Zang received his M.D. from the Shanghai Second Medical University in 1984 and his Ph.D. in Immunology from the University of Brussels in 1991. In 1992, Dr. Zang led a research team at the Willems-Institute in Belgium to develop new therapeutic strategies based on unique T cell technologies. In 1995, Dr. Zang received an award from the National Multiple Sclerosis Society to continue his research on autoimmune -T cells in multiple sclerosis at the Harvard Medical School. He has received many national and international awards and has published over 75 scientific papers and book chapters. Dr. Zang maintains a leading role in Baylor's research and clinical efforts to develop effective therapies for multiple sclerosis. Top Norman Barton, M.D., Ph.D. Dr. Norman Barton is currently Executive Vice President and Chief Medical Officer of Ceptor Corporation. Dr. Barton, who was formally trained in biological chemistry and internal medicine and is a certified specialist in neurology, has had a distinguished career in investigative medicine and in the development of novel therapeutic agents in both the academic and commercial sectors. His many accomplishments include the development of an enzyme replacement therapy for a severely debilitating lipid storage disorder known as Gaucher disease, for which he received both the Outstanding and Meritorious Service Medals of the United States Public Health Service. Prior to joining CepTor, Dr. Barton served as executive vice president and chief medical officer at Osiris Therapeutics (2002-2004), Biotechnology General Corp (1996-2002), and also served as a physician-scientist and Chief of the Clinical Investigations Section with the Neurological Institute at the National Institutes of Health (1985-1996). Dr. Barton received his M.D. and Ph.D. degrees from Pennsylvania State University, and he completed his residency in Internal Medicine at Albany Medical College Hospital and his residency in Neurology at Cornell University New York Hospital. Top Daniel R. Marshak, Ph.D. Dr. Marshak is Senior Vice President – Research and Development, and Chief Technology Officer for Cambrex and a renowned molecular biologist who has served on several NIH Study Sections, the Medical and Scientific Advisory Board of the Dystonia Medical Research Foundation, and the Editorial Board of the Journal of Biological Chemistry. He is also an Adjunct Associate Professor of Oncology and of Molecular Biology & Genetics at the Johns Hopkins University School of Medicine. Prior to joining Cambrex in 2000, Dr. Marshak held various Research and Development positions with Osiris Therapeutics and was a former senior staff investigator at the Cold Spring Harbor Laboratory (1986-1994). Daniel Marshak received his B.A. from Harvard University in biochemistry and molecular biology and his Ph.D. from Rockefeller University. He did postdoctoral research in pharmacology at Vanderbilt University School of Medicine and at the National Institutes of Health. Top Shelly Heimfeld, Ph.D. Dr. Heimfeld is an Associate Faculty Member and serves as the Laboratory Director of the Cellular Therapy and cGMP Cell Processing Facilities at the Fred Hutchinson Cancer Research Center in Seattle, Washington. He has a broad range of research interests, with a particular focus on the development of improved therapeutic strategies using various human stem cell populations. His long-term goals for this area are to identify better markers for the characterization of stem and progenitor cells, to improve isolation technologies for enriching these types of cells, and to develop ex-vivo manipulation strategies that can enhance the therapeutic potential of these cells. Dr. Heimfeld has also been involved in the development of T-cell based immunotherapy for various diseases. Dr. Heimfeld currently serves as President-elect for ISCT (International Society of Cellular Therapy). He is also on the Board of Directors for FACT (Foundation for the Accreditation of Cellular Therapy) and is a leading authority in GLP, GTP and GMP regulations, working with the FDA to facilitate exchange of ideas in the rapidly evolving area of Cell Therapy. Dr. Heimfeld received his Ph.D. in Cell Differentiation from the University of California, Irvine. Top Irun Cohen, M.D. Dr. Irun Cohen was trained as a physician at Northwestern University Medical School and did a residency in pediatrics at the Johns Hopkins Hospital. Since 1968, he has been involved in research in immunology. Dr. Cohen is the Mauerberger Professor of Immunology at the Department of Immunology of the Weizmann Institute of Science. He has served as director, European Collaboration on TCV sponsored by the European Medical Research Councils of the European Science Foundation; director, Robert Koch-Minerva Center for Research in Autoimmune Diseases, at the Weizmann Institute; director, Center for the Study of Emerging Diseases, Jerusalem; Chairman, Committee for the Re-accreditation of Israeli Medical Schools, The Council for Higher Education, Israel; executive director, The National Center for T-cell Vaccination; member of the Executive Committee of The National Center for Complexity Science; and director of the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev. Dr. Cohen was awarded the Robert Koch Prize, Federal Republic of Germany, for his work on autoimmunity. He is a Highly Cited Researcher (ISI), with over 445 professional publications, including the book Tending Adam’s Garden: Evolving the Cognitive Immune Self (Academic Press, 2000). His major contributions include development of cloned T-cells as functional probes for the analysis of autoimmune diseases; discovery of immune regulation by T-cell vaccination; development of the concept of the immunological homunculus in the regulation of autoimmunity, natural and pathogenic; peptide vaccination therapy (peptide p277) of type 1 Autoimmune Diabetes (presently entering Phase III clinical trials); co-inventor of Reactive Animation (a computer-assisted, precise visual language for interactive and dynamic simulation of complex systems); and development of the antigen microarray chip for bioinformatic analysis of immune system patterns. |